Literature DB >> 1446057

Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.

H Naundorf1, E C Rewasowa, I Fichtner, B Büttner, M Becker, M Görlich.   

Abstract

The human mammary carcinomas MT-1 and MT-3 originate from surgical material and were transplanted in nude mice. Both tumors have been classified as estradiol- and progesterone receptor-negative. Therapeutic doses of hormones and anti-hormones remained without growth inhibitory effect. MT-1 and MT-3 proved to be sensitive to conventional cytostatic drugs used for treatment of mammary carcinomas; striking is their sensitivity to ether lipids. Therefore, they are considered suitable tumor models for this class of substances.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1446057     DOI： 10.1007/BF01831480

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.624


  20 in total

Review 1.  [Ether lipids--synthesis and application in tumor therapy].

Authors:  R Zeisig; D Arndt; H Brachwitz
Journal:  Pharmazie       Date:  1990-11       Impact factor: 1.267

2.  An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.

Authors:  G W Bazill; T M Dexter
Journal:  Biochem Pharmacol       Date:  1989-01-15       Impact factor: 5.858

3.  Standards for the assessment of estrogen receptors in human breast cancer. Report of a workshop on September 29, 1972, at the Antoni van Leeuwenhoek-Huis, Amsterdam.

Authors: 
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

4.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

5.  Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.

Authors:  C Unger; M Peukert; H Sindermann; P Hilgard; G Nagel; H Eibl
Journal:  Cancer Treat Rev       Date:  1990-09       Impact factor: 12.111

6.  Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids.

Authors:  G Ostermann; B Hofmann; H P Kertscher; U Till
Journal:  Thromb Res       Date:  1991-02-01       Impact factor: 3.944

7.  Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations.

Authors:  R Zeisig; I Fichtner; D Arndt; S Jungmann
Journal:  Anticancer Drugs       Date:  1991-08       Impact factor: 2.248

Review 8.  Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action.

Authors:  S Ansar Ahmed; W J Penhale; N Talal
Journal:  Am J Pathol       Date:  1985-12       Impact factor: 4.307

9.  Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene.

Authors:  B C Giovanella; D M Vardeman; L J Williams; D J Taylor; P D de Ipolyi; P J Greeff; J S Stehlin; A Ullrich; R Cailleau; D J Slamon
Journal:  Int J Cancer       Date:  1991-01-02       Impact factor: 7.396

10.  Alkyl phosphocholines: toxicity and anticancer properties.

Authors:  C Muschiol; M R Berger; B Schuler; H R Scherf; F T Garzon; W J Zeller; C Unger; H J Eibl; D Schmähl
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880
View more
  9 in total

1.  Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions.

Authors:  Jane Wenzel; Reiner Zeisig; Iduna Fichtner
Journal:  Clin Exp Metastasis       Date:  2009-11-15       Impact factor: 5.150

2.  Carboplatin-liposomes (CPL) in immunodeficient mice: improved antitumor activity for breast carcinomas and stimulation of hematopoiesis.

Authors:  I Fichtner; R Reszka; S R Goan; H Naundorf
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

3.  Establishment and characteristics of two new human mammary carcinoma lines in nude mice with special reference to the estradiol receptor status and the importance of stroma for in vivo and in vitro growth.

Authors:  H Naundorf; I Fichtner; B Elbe; G J Saul; W Haensch; W Zschiesche; S Reinecke
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.

Authors:  I Fichtner; R Zeisig; H Naundorf; S Jungmann; D Arndt; G Asongwe; J A Double; M C Bibby
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer.

Authors:  Flaubert Mbeunkui; Brandon J Metge; Lalita A Shevde; Lewis K Pannell
Journal:  J Proteome Res       Date:  2007-07-04       Impact factor: 4.466

6.  Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice.

Authors:  M C Bibby; M J Thompson; J A Rafferty; G P Margison; R S McElhinney
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

Review 7.  Nuclear protein 1 imparts oncogenic potential and chemotherapeutic resistance in cancer.

Authors:  Anthony Murphy; Max Costa
Journal:  Cancer Lett       Date:  2020-08-22       Impact factor: 8.679

8.  Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance.

Authors:  Vigdis Nygaard; Anders Løland; Marit Holden; Mette Langaas; Håvard Rue; Fang Liu; Ola Myklebost; Øystein Fodstad; Eivind Hovig; Birgitte Smith-Sørensen
Journal:  BMC Genomics       Date:  2003-03-23       Impact factor: 3.969

9.  Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas.

Authors:  H Naundorf; K Parczyk; W Zschiesche; S Reinecke; B Büttner; G J Saul; B Sinn; I Fichtner
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.322
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.